XML 86 R4.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Statements of Changes in Equity
$ in Thousands
CAD ($)
shares
Share Capital
CAD ($)
shares
Reserves
CAD ($)
Share-Based Compensation
CAD ($)
Compensation Options/ Warrants
CAD ($)
Convertible Notes
CAD ($)
Change in Ownership Interest
CAD ($)
AOCI
CAD ($)
Fair Value
CAD ($)
Deferred Tax
CAD ($)
Associate OCI Pick-up
CAD ($)
Foreign Currency Translation
CAD ($)
Retained Earnings (Deficit)
CAD ($)
Non-Controlling Interests
CAD ($)
Beginning balance (in shares) at Jun. 30, 2018 | shares   47,342,761                        
Beginning balance at Jun. 30, 2018 $ 1,552,925 $ 1,466,433 $ (5,285) $ 38,335 $ 307 $ 41,792 $ (85,719) $ (533) $ (539) $ (55) $ 0 $ 61 $ 87,748 $ 4,562
Shares issued for business combinations & asset acquisitions (in shares) | shares   35,943,803                        
Shares issued for business combinations & asset acquisitions 3,163,495 $ 3,060,894 102,601 75,490 27,111                  
Shares issued for earn out payments (in shares) | shares   20,311                        
Shares issued for earn out payments 18,227 $ 18,227                        
Conversion of convertible debentures (in shares) | shares   27,611                        
Conversion of convertible debentures 1,019 $ 1,539 (520)     (520)                
Deferred tax on convertible debentures $ 413 $ 0 413     413                
Exercise of stock options (in shares) | shares 1,202,242 1,202,242                        
Exercise of stock options $ 47,374 $ 108,150 (60,776) (60,776)                    
Exercise of warrants (in shares) | shares   187,685                        
Exercise of warrants 11,939 $ 13,903 (1,964)   (1,964)                  
Exercise of compensation options (in shares) | shares   300                        
Exercise of compensation options 17 $ 38 (21)   (21)                  
Exercise of RSU (in shares) | shares   61,849                        
Exercise of RSUs 0 $ 2,482 (2,482) (2,482)                    
Forfeited options 0   (674) (674)                 674  
Share-based compensation 109,116   109,116 94,054 15,062                  
Contribution from non-controlling interest 5,854                         5,854
Change in ownership interests in subsidiaries 0   (1,081)       (1,081)             1,081
Australis Capital first tranche private placement proceeds 7,800 7,800                        
Australis Capital NCI reclass on loss of control 0 $ (6,348)                       6,348
Spin-out of Australis Capital (158,043)                       (151,695) (6,348)
Reclass gain from Australis Capital shares on derecognition upon spin-out 0             (70,471) (76,873) 6,402     70,471  
Comprehensive income (loss) for the period (372,762)             (72,166) (78,837) 11,948 352 (5,629) (293,509) (7,087)
Ending balance (in shares) at Jun. 30, 2019 | shares [1]   84,786,562                        
Ending balance at Jun. 30, 2019 4,387,374 $ 4,673,118 139,327 143,947 40,495 41,685 (86,800) (143,170) (156,249) 18,295 352 (5,568) (286,311) 4,410
Shares issued for business combinations & asset acquisitions (in shares) | shares [1]   2,689,933                        
Shares issued for business combinations & asset acquisitions 57,420 $ 57,420                        
Shares released for earn out payments (in shares) | shares [1]   614,513                        
Shares released for earn out payments 8,121 $ 15,992 (7,871)   (7,871)                  
Shares issued through equity financings (in shares) | shares [1]   21,009,339                        
Shares issued through equity financing 585,146 $ 585,146                        
Share issuance costs (12,507) (12,507)                        
Deferred tax on share issuance costs 2,231 $ 2,231                        
Conversion of convertible debentures (in shares) | shares [1]   5,761,260                        
Conversion of convertible debentures 391,911 $ 433,177 (41,266)     (41,266)                
Deferred tax on convertible debentures $ 1,785 $ 1,703                     82  
Exercise of stock options (in shares) | shares 103,828 103,841 [1]                        
Exercise of stock options $ 2,794 $ 6,382 (3,588) (3,588)                    
Exercise of warrants (in shares) | shares [1]   986                        
Exercise of warrants 73 $ 102 (29)   (29)                  
Exercise of RSU (in shares) | shares [1]   44,823                        
Exercise of RSUs 0 $ 2,268 (2,268) (2,268)                    
Share-based compensation [2],[3] 61,090   61,090 50,712 10,378                  
Change in ownership interests in subsidiaries (in shares) | shares [1]   217,554                        
Change in ownership interests in subsidiaries 0 $ 20,363                     (18,263) (2,100)
Choom marketable securities transferred to investment in associate 0             4,624 5,225 (601)     (4,624)  
Comprehensive income (loss) for the period (3,358,988)             (48,651) (43,613) 1,225 (379) (5,884) (3,283,671) (26,666)
Ending balance (in shares) at Jun. 30, 2020 | shares [1]   115,228,811                        
Ending balance at Jun. 30, 2020 $ 2,126,450 $ 5,785,395 $ 145,395 $ 188,803 $ 42,973 $ 419 $ (86,800) $ (187,197) $ (194,637) $ 18,919 $ (27) $ (11,452) $ (3,592,787) $ (24,356)
[1] Common share amounts have been retrospectively restated for all prior periods to reflect the Share Consolidation effected on May 11, 2020 (Note 2(a)).
[2] Included in share-based compensation is $10.4 million (June 30, 2019 - $15.1 million) expense relating to milestone payments for the year ended June 30, 2020 of which $5.4 million (June 30, 2019 - $7.4 million) relates to Anandia Laboratories Inc. (Note 12(b)(ii)), $4.5 million (June 30, 2019 - $7.6 million) relates to Whistler Medical Marijuana Corporation (Note 12(b)(v)), and $0.4 million (June 30, 2019 - $0.1 million) relates to an immaterial acquisition.
[3] Of the total $61.1 million share-based compensation reserve, $1.2 million was capitalized to property, plant and equipment for the year ended June 30, 2020 (June 30, 2019 - $2.1 million).